- Home
- GNTA vs IKNA Comparison
GNTA vs IKNA Comparison
Compare GNTA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- IKNA
- Stock Information
- Founded
- GNTA 2014
- IKNA 2016
- Country
- GNTA Italy
- IKNA United States
- Employees
- GNTA N/A
- IKNA N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- IKNA Health Care
- Exchange
- GNTA Nasdaq
- IKNA Nasdaq
- Market Cap
- GNTA 67.4M
- IKNA 83.0M
- IPO Year
- GNTA 2021
- IKNA 2021
- Fundamental
- Price
- GNTA $5.34
- IKNA $1.68
- Analyst Decision
- GNTA Strong Buy
- IKNA Buy
- Analyst Count
- GNTA 1
- IKNA 2
- Target Price
- GNTA $25.00
- IKNA $3.00
- AVG Volume (30 Days)
- GNTA 28.4K
- IKNA 41.6K
- Earning Date
- GNTA 01-01-0001
- IKNA 11-07-2024
- Dividend Yield
- GNTA N/A
- IKNA N/A
- EPS Growth
- GNTA N/A
- IKNA N/A
- EPS
- GNTA N/A
- IKNA N/A
- Revenue
- GNTA N/A
- IKNA $1,844,000.00
- Revenue This Year
- GNTA N/A
- IKNA N/A
- Revenue Next Year
- GNTA N/A
- IKNA N/A
- P/E Ratio
- GNTA N/A
- IKNA N/A
- Revenue Growth
- GNTA N/A
- IKNA N/A
- 52 Week Low
- GNTA $2.20
- IKNA $1.02
- 52 Week High
- GNTA $7.28
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- GNTA 56.89
- IKNA 51.57
- Support Level
- GNTA $4.89
- IKNA $1.68
- Resistance Level
- GNTA $6.20
- IKNA $1.78
- Average True Range (ATR)
- GNTA 0.70
- IKNA 0.04
- MACD
- GNTA -0.06
- IKNA 0.00
- Stochastic Oscillator
- GNTA 37.32
- IKNA 36.36
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.